Comparison of Cyclosporine Concentrations 2 Hours Post-Dose Determined Using 3 Different Methods and Trough Level in Pediatric Renal Transplantation

Rodríguez, Enrique Barrero; Delucchi, Maria A; Cano, Francisco; Valdebenito, Silvana; Castillo, Maria Carmen Gomez del; Villegas, Rodrigo

doi:10.1016/j.transproceed.2005.10.004

Cited by 5 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Adapting the monoclonal FPIA technique (TDx®/TDx FLx®, Abbott Laboratories) currently used for whole blood monitoring to saliva sampling may provide a more precise and specific method for the assessment of CsA salivary concentration;[2129] however, also requires high volumes of saliva. To overcome the need for large amounts of saliva, Masri et al .…”

Section: Discussionmentioning

confidence: 99%

“…[2] In addition to being easier to obtain as part of the patient's ongoing medical care,[2] single serum C 2 measures have been shown to correlate better with AUC 0–4h than trough levels (C 0 ) (CsA blood level before morning dose) and to better reflect the maximal immunosuppressive effect of CsA. [234567] Furthermore, the proportion of cluster of differentiation 4 (CD4+) lymphocytes producing interleukin-2 (IL-2) is the lowest at 2 h post-dose in renal transplant recipients. [8]…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Could salivary cyclosporine dosage replace the whole blood cyclosporine measurements in renal transplant patients?

Masri

Rizk

Chamat

et al. 2017

J Int Soc Prevent Communit Dent

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Could salivary cyclosporine dosage replace the whole blood cyclosporine measurements in renal transplant patients?

Masri

Rizk

Chamat

et al. 2017

J Int Soc Prevent Communit Dent

View full text Add to dashboard Cite

“…The higher CsA concentration measured by various immunoassays versus LC-MS/MS is due to the increased metabolite/CsA ratio in the posttransplantation period [18]. For interpretation of the measured CsA concentrations by immunoassays, the presence of metabolites should be considered to avoid overestimation of CsA results and inadequate immunosuppression of the patients [18], [19]. Correlation to the Abbott Assay was acceptable when the differences between the assays were considered.…”

Section: Discussionmentioning

confidence: 99%

“…The Emit R CSAE is specific for the parent drug and shows no significant interference from CsA metabolites. It has greater specificity and better CsA recovery than the Abbott Assay [19].…”

Section: Discussionmentioning

confidence: 99%

The Emit® 2000 Cyclosporine Specific Assay, Extended Range: Development of an application protocol for the V‐Twin® Analyzer

Morjana

Yau

Rea

et al. 2011

Biotech and App Biochem

View full text Add to dashboard Cite

We evaluated a new protocol for measurement of cyclosporine A (CsA) 2 H after dose (C2) on the V-Twin® analyzer. Imprecision, recovery, and linearity were determined using CsA-spiked blood pools. Accuracy was evaluated using specimens from renal, cardiac, and liver transplant patients, and results were compared with those from liquid chromatography-tandem mass spectrometry (LC-MS/MS) and the Abbott TDx®/TDxFLx® assay. Cross-reactivity and interferences were assessed in the presence of 800 ng/mL CsA. Imprecision coefficients of variation were 3.3%-4.8% (within run) and 5.9%-8.7% (total). Recovery was within 10% of the expected values. Linearity was 350-2,000 ng/mL. Calibration was stable for ≥ 2 weeks. Method comparison showed regression statistics: V-Twin® = 1.01 × LC tandem MS + 36.1, r = 0.971; V-Twin® = 1.13 × Abbott - 92.4, r = 0.969. Metabolite cross-reactivity and interference (endogenous substances and drugs) were within ±10%. The C2 protocol on the V-Twin® analyzer provides acceptable assay performance and accurate determination of whole blood CsA drawn at 2 H after dose.

show abstract

Cyclosporin and methotrexate therapy induces remission in type 1 diabetes mellitus

2010

View full text Add to dashboard Cite

Cyclosporin and methotrexate administration induces remission of type 1 diabetes mellitus. Administration of high-dose cyclosporin (cyclo) has been demonstrated to induce remission of type 1 diabetes mellitus (T1D). Its usefulness was limited by its toxicity. Since methotrexate (mtx) and cyclo synergistically inhibit autoimmune processes, we postulated that low doses of cyclo and mtx could safely induce remission of T1D. In a pilot study, insulin dose requirements and glycemic control were compared in 10 new onset T1D control children with seven children who were administered cyclo at 7.5 mg/kg/day for 6 weeks and then 4 mg/kg/day in addition to mtx 5 mg/kg/wk for 1 year. After 6 weeks, cyclo doses were adjusted to maintain blood cyclo levels 110-220 ng/ml. All children were treated with two daily injections of insulin. Clinical and biochemical toxicity of drug therapy was assessed. There were only very minor adverse effects and no drug induced biochemical test abnormalities. Mean HbA1c levels were similar in the experimental and control groups at baseline and at 3, 6, and 9 months but was lower in the cyclo + mtx group at 12 months. Daily insulin requirements of the groups were similar at baseline but lower in the cyclo + mtx group at 3, 6, 9, and 12 months. Although no control subjects became non-insulin requiring, four of seven cyclo + mtx-treated subjects were entirely off insulin therapy for 2.5, 4.5, 8, and 12 months. Low-dose cyclo and mtx treatment of subjects with new onset T1D can safely induce remission of disease and decrease the amount of required insulin.

show abstract

Comparison of Cyclosporine Concentrations 2 Hours Post-Dose Determined Using 3 Different Methods and Trough Level in Pediatric Renal Transplantation

Cited by 5 publications

References 9 publications

Could salivary cyclosporine dosage replace the whole blood cyclosporine measurements in renal transplant patients?

Could salivary cyclosporine dosage replace the whole blood cyclosporine measurements in renal transplant patients?

The Emit® 2000 Cyclosporine Specific Assay, Extended Range: Development of an application protocol for the V‐Twin® Analyzer

Cyclosporin and methotrexate therapy induces remission in type 1 diabetes mellitus

Contact Info

Product

Resources

About